CNS Pharmaceuticals Q3 net loss narrows to $2.5M
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
CNS Pharmaceuticals, Inc. (CNSP) reported a third-quarter net loss of $2.499 million, versus $3.218 million a year earlier; nine-month net loss was $10.024 million versus $9.895 million. Third-quarter research and development expense fell to $890,000 from $2.197 million as Berubicin trial enrollment and patient treatments were completed, while general and administrative expense rose to $1.775 million from $1.056 million.
As of September 30, 2026, CNSP had $17.212 million in cash and a working-capital surplus of approximately $15.7 million; it used $10.961 million in operating cash over nine months. A May 2026 private placement generated approximately $22.5 million gross and $20.7 million net proceeds through 650,000 common shares and pre-funded warrants to purchase 9,143,479 shares. Management believes existing cash resources are sufficient to fund planned operations beyond twelve months from the statements’ issuance, while stating that advancing drug candidates will require significant additional capital.
As of September 30, 2026, disclosure controls were ineffective due to a material weakness primarily involving lack of segregation of duties because of limited personnel. Management has begun actions to address the lack of formal control documentation, but said these actions will not address the segregation issue. CNSP intends to acquire rights to new assets by the end of 2026.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointThird-quarter net loss narrowed 22.3% to $2.499 million.
Negative
- Major pointMaterial weakness left disclosure controls ineffective as of September 30, 2026.
Filing Explained
At September 30, 2026, all 9,143,479 pre-funded warrants remained unexercised, leaving their potential additional common shares unissued.
Form 10-Q is the unaudited quarterly report; it confirms the May private placement closed, with 650,000 common shares issued and warrants for 9,143,479 more. At quarter-end, none of the warrants had been exercised, so those underlying shares had not been issued; exercise would increase shares outstanding and reduce existing holders’ percentage ownership, absent offsetting changes.
The warrants were exercisable immediately for one common share each at
Common shares outstanding were 1,475,699 on
Key Figures
Key Terms
pre-funded warrants technical
material weakness technical
working capital surplus financial
going concern financial
anti-dilutive financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much cash did CNSP report at September 30, 2026?
What are the terms of CNSP’s May 2026 pre-funded warrants?
AI-generated analysis. How Rhea-AI works. Not financial advice.
Table of Contents
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
For the quarterly period ended
OR
For the transition period from ____________ to ______________
Commission file number:

(Name of registrant as specified in its charter)
| (State or other jurisdiction of Incorporation or Organization) | (I.R.S. Employer identification No.) |
|
|
|
| (Address of principal executive offices) | (Zip Code) |
(Registrant’s telephone number, including area code)
N/A
(Former name or former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol | Name of Each Exchange on Which Registered |
| The |
Indicate by check mark whether the registrant (1) filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically
every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the
preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:
| Large accelerated Filer ☐ | Accelerated Filer ☐ |
| Smaller reporting company | |
| Emerging Growth Company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as
defined in Rule 12b-2 of the Exchange Act). Yes ☐ No
The number of shares outstanding of the registrant’s common stock,
par value $0.001 per share, as of November 15, 2026 was
TABLE OF CONTENTS
| Page | ||
| PART I FINANCIAL INFORMATION | ||
| Item 1. | Financial Statements | 3 |
| Balance Sheets as of September 30, 2026 and December 31, 2025 (unaudited) | 3 | |
| Statements of Operations for the three and nine months ended September 30, 2026 and 2025 (unaudited) | 4 | |
| Statements of Stockholders’ Equity for the three and nine months ended September 30, 2026 and 2025 (unaudited) | 5 | |
| Statements of Cash Flows for the nine months ended September 30, 2026 and 2025 (unaudited) | 6 | |
| Notes to the Financial Statements (unaudited) | 7 | |
| Item 2. | Management's Discussion and Analysis of Financial Condition and Results of Operations | 15 |
| Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 21 |
| Item 4. | Controls and Procedures | 21 |
| PART II OTHER INFORMATION | ||
| Item 1. | Legal Proceedings | 22 |
| Item 1A. | Risk Factors | 22 |
| Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 22 |
| Item 3. | Defaults Upon Senior Securities | 22 |
| Item 4. | Mine Safety Disclosures | 22 |
| Item 5. | Other Information | 22 |
| Item 6. | Exhibits | 23 |
| Signatures | 24 | |
| 2 |
PART I - FINANCIAL INFORMATION
| ITEM 1. | FINANCIAL STATEMENTS |
CNS Pharmaceuticals, Inc.
Balance Sheets
(in thousands, except share and per share amounts)
(Unaudited)
| September 30, 2026 | December 31, 2025 | |||||||
| Assets | ||||||||
| Current Assets: | ||||||||
| Cash and cash equivalents | $ | $ | ||||||
| Deferred offering costs | ||||||||
| Prepaid expenses and other current assets | ||||||||
| Total current assets | ||||||||
| Noncurrent Assets: | ||||||||
| Prepaid expenses, net of current portion | ||||||||
| Property and equipment, net | ||||||||
| Total noncurrent assets | ||||||||
| Total Assets | $ | $ | ||||||
| Liabilities and Stockholders' Equity | ||||||||
| Current Liabilities: | ||||||||
| Accounts payable and accrued expenses | $ | $ | ||||||
| Notes payable | ||||||||
| Total current liabilities | ||||||||
| Total Liabilities | ||||||||
| Commitments and contingencies (Note 5) | – | – | ||||||
| Stockholders' Equity: | ||||||||
| Preferred stock, $ | ||||||||
| Common stock, $ | ||||||||
| Additional paid-in capital | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Total Stockholders' Equity | ||||||||
| Total Liabilities and Stockholders' Equity | $ | $ | ||||||
See accompanying notes to the unaudited financial statements.
| 3 |
CNS Pharmaceuticals, Inc.
Statements of Operations
(in thousands, except share and per share amounts)
(Unaudited)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | $ | $ | $ | $ | ||||||||||||
| General and administrative | ||||||||||||||||
| Total operating expenses | ||||||||||||||||
| Loss from operations | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Interest income | ||||||||||||||||
| Interest expense | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Total other income | ||||||||||||||||
| Net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Loss per share - basic | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Loss per share - diluted | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Weighted average shares outstanding - basic | ||||||||||||||||
| Weighted average shares outstanding - diluted | ||||||||||||||||
See accompanying notes to the unaudited financial statements.
| 4 |
CNS Pharmaceuticals, Inc.
Statements of Stockholders' Equity
(in thousands, except share amounts)
(Unaudited)
| Additional | Total | |||||||||||||||||||
| Common Stock | Paid-in | Accumulated | Stockholders' | |||||||||||||||||
| Shares | Amount | Capital | Deficit | Equity | ||||||||||||||||
| Balance, December 31, 2024 | $ | $ | $ | ( | ) | $ | ||||||||||||||
| Common stock issued for cash, net | – | – | ||||||||||||||||||
| Stock repurchase during stock split rounding | ( | ) | – | ( | ) | – | ( | ) | ||||||||||||
| Stock-based compensation | – | – | – | |||||||||||||||||
| Net loss | – | – | – | ( | ) | ( | ) | |||||||||||||
| Balance, March 31, 2025 | ( | ) | ||||||||||||||||||
| Common stock issued for cash, net | – | – | ||||||||||||||||||
| Stock issued for warrants exercised | – | – | ||||||||||||||||||
| Stock-based compensation | – | – | – | |||||||||||||||||
| Net loss | – | – | – | ( | ) | ( | ) | |||||||||||||
| Balance, June 30, 2025 | ( | ) | ||||||||||||||||||
| Stock cancelled during stock split rounding | ( | ) | – | ( | ) | – | ( | ) | ||||||||||||
| Stock issued for warrants exercised | – | – | ||||||||||||||||||
| Stock-based compensation | – | – | – | |||||||||||||||||
| Deferred offering costs | – | – | ( | ) | – | ( | ) | |||||||||||||
| Net loss | – | – | – | ( | ) | ( | ) | |||||||||||||
| Balance, September 30, 2025 | $ | $ | $ | ( | ) | $ | ||||||||||||||
| Balance, December 31, 2025 | $ | $ | $ | ( | ) | $ | ||||||||||||||
| Common stock issued for cash, net | – | – | ||||||||||||||||||
| Stock-based compensation | – | – | – | |||||||||||||||||
| Net loss | – | – | – | ( | ) | ( | ) | |||||||||||||
| Balance, March 31, 2026 | ( | ) | ||||||||||||||||||
| Issuance of common stock and pre-funded warrants, net of offering costs | – | |||||||||||||||||||
| Stock-based compensation | – | – | – | |||||||||||||||||
| Net loss | – | – | – | ( | ) | ( | ) | |||||||||||||
| Balance, June 30, 2026 | ( | ) | ||||||||||||||||||
| Stock-based compensation | – | – | – | |||||||||||||||||
| Issuance of common stock for vested RSUs | – | ( | ) | – | ( | ) | ||||||||||||||
| Net loss | – | – | – | ( | ) | ( | ) | |||||||||||||
| Balance, September 30, 2026 | $ | $ | $ | ( | ) | $ | ||||||||||||||
See accompanying notes to the unaudited financial statements.
| 5 |
CNS Pharmaceuticals, Inc.
Statements of Cash Flows
(in thousands)
(Unaudited)
| Nine Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| Cash Flows from Operating Activities: | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Stock-based compensation | ||||||||
| Depreciation | ||||||||
| Changes in operating assets and liabilities: | ||||||||
| Prepaid expenses and other current assets | ( | ) | ||||||
| Deferred offering costs | ( | ) | ||||||
| Accounts payable and accrued expenses | ( | ) | ( | ) | ||||
| Net cash used in operating activities | ( | ) | ( | ) | ||||
| Cash Flows from Investing Activities: | ||||||||
| Purchase of property and equipment | ( | ) | ||||||
| Net cash used in investing activities | ( | ) | ||||||
| Cash Flows from Financing Activities: | ||||||||
| Payments of deferred offering costs | ( | ) | ||||||
| Payments on notes payable | ( | ) | ( | ) | ||||
| Proceeds from exercises, including future exercises, of warrants | ||||||||
| Payments to stockholders for stock split rounding | ( | ) | ||||||
| Proceeds from subscription receivable | ||||||||
| Proceeds from sale of common stock and pre-funded warrants, net | ||||||||
| Net cash provided by financing activities | ||||||||
| Net change in cash and cash equivalents | ||||||||
| Cash and cash equivalents, at beginning of period | ||||||||
| Cash and cash equivalents, at end of period | $ | $ | ||||||
| Supplemental disclosures of cash flow information: | ||||||||
| Cash paid for interest | $ | $ | ||||||
| Cash paid for income taxes | $ | $ | ||||||
| Supplemental disclosure of non-cash investing and financing activities: | ||||||||
| Prepaid insurance financed with note payable | $ | $ | ||||||
| Amortization of deferred offering costs to equity | $ | $ | ||||||
See accompanying notes to the unaudited financial statements.
| 6 |
CNS Pharmaceuticals, Inc.
Notes to the Financial Statements
(Unaudited)
Note 1 – Nature of Business
CNS Pharmaceuticals, Inc. (“we”, “our”,
the “Company”) is a biotechnology company organized as a Nevada corporation in July 2017. In the first quarter of 2026, the
Company announced the formation of a new executive team as well as a new corporate strategy focused on securing the rights to and developing
innovative therapies for serious diseases and pivoting from a singular focus on glioblastoma multiforme by exploring out-licensing opportunities
for its legacy assets TPI 287 and Berubicin for which the Company has intellectual property rights under license agreement with Cortice
and owns pursuant to a collaboration and asset purchase agreement with Reata. To execute the new corporate strategy, the Company is leveraging
its executive team’s multi-functional experiences across high-value therapeutic areas including but not limited to neurology, oncology
or rare diseases. In May 2026, the Company completed a $
Note 2 – Summary of Significant Accounting Policies
Basis of Presentation - The accompanying unaudited financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim unaudited financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. The unaudited financial statements include all adjustments (consisting of normal recurring adjustments) which are, in the opinion of the Company, necessary in order to make the financial statements not misleading. Operating results for the nine months ended September 30, 2026 are not necessarily indicative of the final results that may be expected for the year ending December 31, 2026. For more complete financial information, these unaudited financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2025 included in our Form 10-K filed with the SEC on March 31, 2026 (“Form 10-K”). Notes to the financial statements which would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal period, as reported in the Form 10-K, have been omitted.
Liquidity
and Going Concern - Since inception, the Company has a history of net losses and negative cash flows from
operations. For the nine months ended September 30, 2026, the Company recorded a net loss of approximately $10.0
million and used cash in operations of approximately $11.0
million. As of September 30, 2026, the Company had an accumulated deficit of approximately $110.3
million and cash of approximately $
Cash
and Cash Equivalents - The Company considers all highly liquid accounts with original maturities of three months or
less at the date of acquisition to be cash equivalents. Periodically, the Company may carry cash balances at financial institutions in
excess of the federally insured limit of $250,000. The Company did
| 7 |
Property and Equipment - Property and equipment is recorded at cost and depreciated over their estimated useful lives using the straight-line depreciation method as follows:
| Schedule of estimated useful lives | |
| Leasehold improvement | Shorter of estimated useful lives or the term of the lease |
| Computer equipment | |
| Machinery and equipment | |
| Furniture and office equipment |
Repairs and maintenance costs are expensed as incurred.
Related Parties - The Company follows Accounting Standards Codification (“ASC”) 850, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.
Stock-based Compensation - Employee and non-employee share-based compensation is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period for stock options and restricted stock units.
Restricted Stock Units (“RSUs”) - Our RSUs fully vest over two to four years from the date of grant. The fair value of RSUs is the market price of our common stock at the date of grant. The Company reverses any previously recognized compensation cost associated with forfeited RSUs in the period which the forfeiture occurs.
Performance Units (“PUs”) - The PUs vest based on our performance against predefined share price targets and the achievement of Positive Interim Clinical Data as defined by the Board.
Warrants - The Company evaluates all freestanding and embedded warrants to determine whether they meet the criteria for equity classification under ASC 815-40, Derivatives and Hedging—Contracts in Entity’s Own Equity, or if they must be classified as liabilities under ASC 480 or ASC 815-10. The Company evaluated the warrants and concluded they are indexed to the Company's common stock and meet the equity classification criteria under ASC 815-40, as they are settleable in shares and the Company has sufficient shares authorized. The warrants were recorded at fair value upon issuance within stockholders' equity.
Loss Per Common Share - Basic loss per common share is computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents because their inclusion would be anti-dilutive.
Segment Reporting - The Company manages its operations as a single segment for the purpose of assessing performance and making operating decisions. The Company’s Chief Operating Decision Maker (“CODM”) is its Chief Executive Officer. The CODM allocates resources and evaluates the performance of the Company using information about combined net loss from operations. All significant operating decisions are based upon an analysis of the Company as one operating segment, which is the same as its reporting segment. See statement of operations for information about combined net loss from operations.
Recent Accounting Pronouncements - In November 2024, the FASB issued Accounting Standards Update No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40) (“ASU 2024-03”). ASU 2024-03 requires specified information about certain costs and expenses be disclosed in the notes to the financial statements, including the expense caption on the face of the income statement in which they are disclosed, in addition to a qualitative description of remaining amounts not separately disaggregated. Entities will also be required to disclose their definition of “selling expenses” and the total amount in each annual period. The standard is effective for the Company for annual periods beginning January 1, 2027 and for interim periods beginning January 1, 2028, with updates applied either prospectively or retrospectively. Early adoption is permitted. The Company is currently evaluating the impact of this guidance on its disclosures.
| 8 |
Note 3 – Note Payable
On November 8, 2025, the Company entered into a
short-term note payable for an aggregate of $
Note 4 – Equity
The Company has authorized
On July 22, 2025, the Company effected a reverse
stock split on a
On November 20, 2025, following approval by shareholders,
the Company filed a Certificate of Amendment to its Amended and Restated Articles of Incorporation with the Secretary of State of the
State of Nevada to increase the number of the Company’s authorized shares of common stock from
Common Stock and Pre-Funded Warrants
On May 4, 2026, the Company entered into a Securities
Purchase Agreement (the “Purchase Agreement”) with institutional investors (the “Investors”), pursuant to which
the Investors purchased in a private placement: (i)
Subject to certain ownership limitations, the Pre-Funded
Warrants are exercisable immediately upon issuance into one share of common stock at an exercise price per share of $0.001 (as adjusted
from time to time in accordance with the terms thereof) and expire once such Pre-Funded Warrant is fully exercised. The holder of a Pre-Funded
Warrant is prohibited from exercising any Pre-Funded Warrants to the extent that such exercise would result in the number of shares of
common stock beneficially owned by such holder and its affiliates exceeding 4.99% (or 9.99% as applicable) of the total number of shares
of common stock outstanding immediately after giving effect to the exercise, which percentage may be increased or decreased at the holder’s
election not to exceed 9.99%. The gross proceeds to the Company from the Offering were approximately $
| 9 |
On July 26, 2024, the Company entered into a Sales Agreement (the “AGP ATM Sales Agreement”) with A.G.P./Alliance Global Partners (“AGP”). Pursuant to the terms of the AGP ATM Sales Agreement, the Company originally was permitted to sell from time to time through AGP, as sales agent or principal, shares of the Company’s common stock with initial aggregate sales price of up to $5.2 million. On September 19, 2025, the Company decreased the sales price of common shares that may be sold under the AGP ATM Sales Agreement to $1.8 million, which amount does not include any shares of common stock sold prior to such date.
On May 13, 2025, the Company entered into a placement
agency agreement (the “Placement Agency Agreement”) with A.G.P./Alliance Global Partners (the “Placement Agent”)
for the public offering by the Company of (i)
Subject to certain ownership limitations, the Warrants are exercisable immediately upon issuance. Each Pre-Funded A.G.P. Warrant is exercisable into one share of common stock at a price per share of $0.001 and expire once such Pre-Funded A.G.P. Warrants are fully exercised. The Common Warrants are exercisable into one share of Common Stock at a price per share of $13.68 and expire five years from Initial Exercise Date. The closing of this offering occurred on May 14, 2025.
The following table summarizes the common stock and pre-funded warrant activity for the nine months ended September 30, 2026 and 2025 (in thousands, except share amounts):
| Schedule of pre funded warrant activity | ||||||||||||||||
| Nine Months Ended September 30, | ||||||||||||||||
| 2026 | 2025 | |||||||||||||||
| Shares | $ | Shares | $ | |||||||||||||
| Purchase Agreement | $ | $ | ||||||||||||||
| Pre-Funded Warrants | ||||||||||||||||
| AGP ATM Sales Agreement, net | ||||||||||||||||
| Common stock and Common Warrant | ||||||||||||||||
| Common stock and Pre-Funded A.G.P. Warrants | ||||||||||||||||
| Total | $ | $ | ||||||||||||||
Stock Options
In 2020, the Board of Directors of the Company approved the CNS Pharmaceuticals,
Inc. 2020 Stock Plan (the “2020 Plan”). The 2020 Plan allows for the Board of Directors to grant various forms of equity incentive
awards. On September 30, 2026, the
Company held its scheduled 2026 Annual Meeting of Stockholders at which the Company’s stockholders approved amendments to the
Company's 2020 Stock Plan including an increase in the number of shares of common stock authorized for issuance under the 2020 Plan
by
| 10 |
The following table summarizes the stock option activity for the nine months ended September 30, 2026:
| Schedule of stock option activity | ||||||||
| Options | Weighted-Average Exercise Price Per Share | |||||||
| Outstanding, December 31, 2025 | $ | |||||||
| Granted | $ | |||||||
| Exercised | $ | |||||||
| Forfeited | ( | ) | $ | |||||
| Expired | ( | ) | $ | |||||
| Outstanding, September 30, 2026 | $ | |||||||
| Exercisable, September 30, 2026 | $ | |||||||
As of September 30, 2026, the outstanding stock
options have a weighted average remaining term of
Restricted Stock Units
The following table summarizes the RSUs activity for the nine months ended September 30, 2026:
| Schedule of RSUs activity | ||||||||
| RSUs | Weighted-Average Grant Date Fair Value | |||||||
| Non-vested, December 31, 2025 | $ | |||||||
| Granted | $ | |||||||
| Vested | ( | ) | $ | |||||
| Forfeited | ( | ) | $ | |||||
| Non-vested, September 30, 2026 | $ | |||||||
Performance Units
The following table summarizes the PUs activity for the nine months ended September 30, 2026:
| schedule of PUs activity | ||||||||
| PUs | Weighted-Average Grant Date Fair Value | |||||||
| Non-vested – December 31, 2025 | $ | |||||||
| Granted | $ | |||||||
| Vested | $ | |||||||
| Forfeited/Cancelled | ( | ) | $ | |||||
| Non-vested, September 30, 2026 | $ | |||||||
| 11 |
Stock-Based Compensation Expense
The following table summarizes stock-based compensation expense for the three and nine months ended September 30, 2026 and 2025 (in thousands):
| Schedule of stock based compensation | ||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Stock options | $ | $ | $ | ( |
) | $ | ||||||||||
| RSUs | ||||||||||||||||
| Total | $ | $ | $ | $ | ||||||||||||
At September 30, 2026, the Company had $
Note 5 – Commitments and Contingencies
Executive Employment Agreements
On December 16, 2025, John Climaco resigned from
his positions as chief executive officer of the Company and as a member of the Company’s Board of Directors. The Company and Mr.
Climaco entered into a Separation and Severance Agreement dated as of December 16, 2025 (the “Separation Agreement”), which
memorializes the terms of his resignation and separation from service with the Company. Pursuant to the Separation Agreement, subject
to Mr. Climaco’s timely execution, non-revocation, and compliance with the agreement’s terms, the Company is providing severance
benefits, including (i) severance equal to twelve months of Mr. Climaco’s current annualized base salary, paid in twelve equal monthly
installments, and payment of his base salary through December 31, 2025; (ii) payment of Mr. Climaco’s 2025 cash bonus in the total
amount of $
Reata Agreement
On November 21, 2017, the Company entered into a Collaboration and Asset Purchase Agreement with Reata Pharmaceuticals, Inc. (“Reata”). Through this agreement, the Company purchased all of Reata’s rights, title, interest and previously conducted research and development results in the chemical compound commonly known as Berubicin. In exchange for these rights, the Company agreed to pay Reata an amount equal to 2.25% of the net sales of Berubicin for a period of 10 years from the Company’s first commercial sale of Berubicin plus $10,000. Reata also agreed to collaborate with the Company on the development of Berubicin, from time to time.
| 12 |
Cortice Biosciences, Inc. Exclusive License Agreement
On July 29, 2024, the Company entered into an Exclusive License Agreement (the “Cortice Agreements”) with Cortice Biosciences, Inc. (“Cortice”) pursuant to which Cortice granted the Company an exclusive license to the intellectual property rights related to certain patents around the compound TPI 287 in the United States, Canada, Mexico and Japan. The term of the license will expire, other than due to a breach of the Cortice Agreements, at the end of the royalty term with respect to any licensed product in any of the included territories, which begins upon the first commercial sale in such territory and ends on the latest of (i) ten years after such sale, (ii) the expiration of regulatory or marketing exclusivity for such licensed product in such country, or (iii) the expiration of the last to expire valid patent claim in such country covering such licensed product. Pursuant to the Cortice Agreements, the Company agreed to issue Cortice 956 shares of the Company’s common stock upon the closing of the transaction, which occurred on July 29, 2024, and 73 shares of Company common stock upon the receipt of shareholder approval of such issuance as required by the rules of the Nasdaq Stock Market. The Company also agreed to make milestone payments to Cortice in either cash or shares of Company common stock (at Cortice’s option) upon: (i) meeting the primary endpoint of a pivotal trial for a licensed product – either $15.0 million or 686 shares of Company common stock; (ii) FDA acceptance of a New Drug Application for a licensed product – either $30.0 million or 1,371 shares of Company common stock; (iii) the first commercial sale in the United States of a licensed product – either $45.0 million or 2,056 shares of Company common stock; and (iv) the first commercial sale in Japan of a licensed product – either $10.0 million or 343 shares of Company common stock. The Company’s obligation to pay the above milestones in Company common stock is subject to the receipt of shareholder approval as required by the rules of the Nasdaq Stock Market. The Company also agreed to pay Cortice royalties on sales of licensed products of between 3.0%-7.5%. Finally, to the extent Cortice is required to pay any milestone payments to the original holder of the intellectual property rights licensed, the Company has agreed to make such payments to Cortice. As of September 30, 2026, there were no accruals related to the milestone payments.
Note 6 – Earnings Per Share
The following potentially dilutive securities have been excluded from the diluted per share calculations as they would be anti-dilutive:
| Schedule of anti-dilutive shares | ||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Warrants | ||||||||||||||||
| RSUs | ||||||||||||||||
| Stock options | ||||||||||||||||
| PUs | ||||||||||||||||
Outstanding pre-funded warrants as of September 30, 2026 are
| 13 |
Note 7 – Fair Value Measurements
The following table presents information about our financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):
| Schedule of fair value measurements | ||||||||||||||||
| September 30, 2026 | ||||||||||||||||
| Total | Level 1 | Level 2 | Level 3 | |||||||||||||
| Assets | ||||||||||||||||
| Money market fund | $ | $ | $ | $ | ||||||||||||
| Bank deposit account | ||||||||||||||||
| Total | $ | $ | $ | $ | ||||||||||||
| December 31, 2025 | ||||||||||||||||
| Total | Level 1 | Level 2 | Level 3 | |||||||||||||
| Assets | ||||||||||||||||
| Bank deposit account | $ | $ | $ | $ | ||||||||||||
| Total | $ | $ | $ | $ | ||||||||||||
Money market funds and bank deposit accounts are included within cash and cash equivalents in the accompanying balance sheets and are recognized at fair value. As of September 30, 2026 and December 31, 2025, the Company only held Level 1 financial instruments and there were no transfers among levels.
| 14 |
| ITEM 2. | MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS |
You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the financial statements and the related notes appearing elsewhere in this Form 10-Q. This discussion contains forward-looking statements reflecting our current expectations that involve risks and uncertainties. See Item 1A. “Risk Factors” of our Form 10-K for the year ended December 31, 2025, available on the Securities and Exchange Commission's (“SEC”) EDGAR website at www.sec.gov, for a discussion of the uncertainties, risks and assumptions associated with these statements. Actual results and the timing of events could differ materially from those discussed in our forward-looking statements as a result of many factors, including those set forth under “Risk Factors” and elsewhere in this Form 10-Q.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
We make forward-looking statements under the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and in other sections of this Form 10-Q. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “should,” “would,” “could,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential” or “continue,” and the negative of these terms and other comparable terminology. These forward-looking statements, which are subject to known and unknown risks, uncertainties and assumptions about us, may include projections of our future financial performance based on our growth strategies and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. In particular, you should consider the numerous risks and uncertainties described under Item 1A. “Risk Factors” of our Form 10-K for the year ended December 31, 2025 and in other filings made by us from time to time with the SEC.
While we believe we have identified material risks, these risks and uncertainties are not exhaustive. Other sections of this Form 10-Q may describe additional factors that could adversely impact our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible to predict all risks and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.
Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy or completeness of any of these forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. We are under no duty to update any of these forward-looking statements after the date of this Form 10-Q to conform our prior statements to actual results or revised expectations, and we do not intend to do so. In addition, with respect to all of our forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
| 15 |
Forward-looking statements include, but are not limited to, statements about:
| · | our ability to secure rights to new pipeline assets; | |
| · | our ability to obtain additional funding to acquire rights to and develop pipeline assets; | |
| · | our ability to maintain compliance with the NASDAQ Capital Market’s continued listing requirements, including any new continued listing requirements that are approved in the future; | |
| · | the success of our research and development efforts and clinical trials through all phases of clinical development; | |
| · | the need to obtain regulatory approval of our product candidates; | |
| · | compliance with obligations under intellectual property licenses with third parties; | |
| · | any delays in regulatory review and approval of product candidates in clinical development; | |
| · | our ability to commercialize our product candidates; | |
| · | market acceptance of our product candidates; | |
| · | competition from existing products or new products that may emerge; | |
| · | potential product liability claims; | |
| · | our dependency on third-party manufacturers to supply or manufacture our products; | |
| · | our ability to establish or maintain collaborations, licensing or other arrangements; | |
| · | our ability and third parties’ abilities to protect intellectual property rights; | |
| · | our ability to adequately support future growth; and | |
| · | our ability to attract and retain key personnel to manage our business effectively. |
We caution you not to place undue reliance on the forward-looking statements, which speak only as of the date of this Form 10-Q in the case of forward-looking statements contained in this Form 10-Q.
| 16 |
Overview
CNS Pharmaceuticals, Inc. (“we”, “our”, the “Company”) is a biotechnology company organized as a Nevada corporation in July 2017. In the first quarter of 2026, we announced the formation of a new executive team as well as a new corporate strategy focused on securing the rights to and developing innovative therapies for serious diseases and pivoting from a singular focus on glioblastoma multiforme by exploring out-licensing opportunities for our legacy assets TPI 287 and Berubicin. To execute our new corporate strategy, we are leveraging our executive team’s multi-functional experiences across high-value therapeutic areas including but not limited to neurology, oncology or rare diseases. In May 2026, we completed a $22.5 million private placement with biotechnology focused institutional investors to support the execution of the corporate strategy. We intend to acquire the rights to a new asset or assets by the end of 2026.
Results of Operations
Comparison of the three months ended September 30, 2026 and 2025
The following sets forth our results of operations (in thousands):
| Three Months Ended September 30, | Change | |||||||||||||||
| 2026 | 2025 | Amount | % | |||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | $ | 890 | $ | 2,197 | $ | (1,307 | ) | -59.5% | ||||||||
| General and administrative | 1,775 | 1,056 | 719 | 68.1% | ||||||||||||
| Total operating expenses | 2,665 | 3,253 | (588 | ) | -18.1% | |||||||||||
| Loss from operations | (2,665 | ) | (3,253 | ) | 588 | -18.1% | ||||||||||
| Other income (expense): | ||||||||||||||||
| Interest income | 169 | 37 | 132 | 356.8% | ||||||||||||
| Interest expense | (3 | ) | (2 | ) | (1 | ) | 50.0% | |||||||||
| Total other income | 166 | 35 | 131 | 374.3% | ||||||||||||
| Net loss | $ | (2,499 | ) | $ | (3,218 | ) | $ | 719 | -22.3% | |||||||
Research and Development Expense
Research and development expense was approximately $0.9 million and $2.2 million for the three months ended September 30, 2026 and 2025, respectively. The decrease of $1.3 million is primarily related to a decrease in costs related to Berubicin of approximately $1.2 million. The decrease in costs related to Berubicin are primarily related to the closing out of the clinical trial for Berubicin as enrollment and patient treatments have been completed. The decrease also reflects lower TPI 287 manufacturing costs of approximately $0.5 million. These decreases are partially offset by an increase in personnel related expenses of $0.4 million. Our future research and development expense will be dependent on the timing and nature of any new asset we in-license or acquire and the development expenses related to such asset.
| 17 |
General and Administrative Expense
General and administrative expense was approximately $1.8 million and $1.1 million for the three months ended September 30, 2026 and 2025, respectively. The increase of $0.7 million in general and administrative expense was attributable to increases in consulting services of $0.5 million, primarily related to business development, and headcount related expenses of $0.4 million. These increases were partially offset by a decrease in professional services, including accounting consulting and investor relations fees, of $0.2 million.
Other Income (Expense)
Other income (expense) was approximately $0.2 million and $0.04 million for the three months ended September 30, 2026 and 2025, respectively. The increase in other income was mainly due to an increase in interest income due to higher cash balances in our money market accounts.
Comparison of the nine months ended September 30, 2026 and 2025
The following sets forth our results of operations (in thousands):
| Nine Months Ended September 30, | Change | |||||||||||||||
| 2026 | 2025 | Amount | % | |||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | $ | 5,636 | $ | 6,607 | $ | (971 | ) | -14.7% | ||||||||
| General and administrative | 4,705 | 3,393 | 1,312 | 38.7% | ||||||||||||
| Total operating expenses | 10,341 | 10,000 | 341 | 3.4% | ||||||||||||
| Loss from operations | (10,341 | ) | (10,000 | ) | (341 | ) | 3.4% | |||||||||
| Other income (expense): | ||||||||||||||||
| Interest income | 330 | 118 | 212 | 179.7% | ||||||||||||
| Interest expense | (13 | ) | (13 | ) | – | –% | ||||||||||
| Total other income | 317 | 105 | 212 | 201.9% | ||||||||||||
| Net loss | $ | (10,024 | ) | $ | (9,895 | ) | $ | (129 | ) | 1.3% | ||||||
Research and Development Expense
Research and development expense was approximately $5.6 million and $6.6 million for the nine months ended September 30, 2026 and 2025, respectively. The decrease in research and development expense of $1.0 million is primarily attributable to a decrease in clinical costs related to Berubicin of $2.6 million due to the closing out of the clinical trial for Berubicin as enrollment and patient treatments have been completed. This decrease is partially offset by an increase in personnel and personnel related costs of $1.6 million. Our future research and development expense will be dependent on the timing and nature of any new asset we in-license or acquire and the development expenses related to such asset.
| 18 |
General and Administrative Expense
General and administrative expense was approximately $4.7 million and $3.4 million for the nine months ended September 30, 2026 and 2025, respectively. The increase in general and administrative expense of $1.3 million was attributable to increases of approximately $0.8 million in personnel related expenses, $0.7 million in consulting costs, mainly attributable to business development and $0.3 million in recruiting costs. These increases were partially offset by a decrease in investor relations expenses of $0.3 million and accounting fees of $0.2 million.
Other Income (Expense)
Other income (expense) was approximately $0.3 million and $0.1 million for the nine months ended September 30, 2026 and 2025, respectively. The increase in other income was mainly due to an increase in interest income due to higher cash balances in our money market accounts.
Liquidity and Capital Resources
On September 30, 2026, we had cash of approximately $17.2 million and we had a working capital surplus of approximately $15.7 million. We have historically funded our operations from proceeds from debt and equity sales.
On July 26, 2024, we entered into a Sales Agreement (the “AGP ATM Sales Agreement”) with A.G.P./Alliance Global Partners (“AGP”). Pursuant to the terms of the AGP ATM Sales Agreement, we are permitted to sell from time to time through AGP, as sales agent or principal, shares of our common stock. During the period ended September 30, 2026, the Company sold 178,933 shares of common stock pursuant to the AGP ATM Sales Agreement for net proceeds of approximately $0.5 million. As of September 30, 2026, the Company sold 447,102 shares of common stock pursuant to the AGP ATM Sales Agreement for net proceeds of approximately $23.7 million since entering into the Sales Agreement in July 2024.
On May 4, 2026, we entered into a Purchase Agreement for a private placement financing that resulted in gross proceeds of approximately $22.5 million. Pursuant to the terms of the Purchase Agreement, we sold an aggregate of (i) 650,000 shares of our common stock at a purchase price of $2.30 per share and (ii) pre-funded warrants to purchase 9,143,479 shares of common stock at a purchase price of $2.299 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.001 per share. The private placement closed on May 5, 2026.
We believe that the net proceeds from this financing, combined with our existing cash resources, are sufficient to fund planned operations beyond twelve months from the date these financial statements are issued. Our strategy is focused on identifying and securing the rights to development stage assets and advancing any assets we obtain the rights to. The timing, cost and ultimate success of which are all difficult to predict and as such the foregoing estimate may prove to be inaccurate. The cost of advancing any drug candidate will require significant additional capital. We have no commitments for such additional needed financing and will likely be required to raise additional capital through the sale of additional equity or debt securities.
We will need to raise significant additional capital in the future in order to meet our future obligations and execute our business plan. If we are unable to execute our business plan, we will be required to develop and implement an alternative plan to further extend payables, reduce overhead or scale back our business plan until sufficient additional capital is raised to support further operations and the execution of our business plan. There can be no assurance that such a plan will be successful and if it is not successful we may need to cease operations entirely.
| 19 |
Summary of Cash Flows
Cash used in operating activities
Net cash used in operating activities was approximately $11.0 million and $10.8 million for the nine months ended September 30, 2026 and 2025, respectively, and mainly included payments made for clinical trial costs, officer compensation, insurance, consulting fees, attorneys and accountants.
Cash used in investing activities
Net cash used in investing activities was de minimis for the nine months ended September 30, 2026 and 2025.
Cash provided by financing activities
Net cash provided by financing activities was approximately $21.0 million and $14.2 million for the nine months ended September 30, 2026 and 2025, respectively. Net cash provided by financing activities for the nine months ended September 30, 2026 included proceeds from the Offering and AGP ATM Sales Agreement, partially offset by the repayments on the notes payable. Net cash provided by financing activities for the nine months ended September 30, 2025 related to the sale of common stock and proceeds from our subscription receivable related to the AGP ATM Sales Agreement, which were partially offset by the repayments of notes payable.
Off-balance Sheet Arrangements
As of September 30, 2026, we did not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes.
Purchase Commitments
We do not have any material commitments for capital expenditures, although we are required to pay certain milestone payments and royalties to Cortice and contingent royalties to Reata as described in Note 5 - Commitments and Contingencies to the financial statements included elsewhere in this Form 10-Q.
Critical Accounting Policies and Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates, assumptions and judgments that affect the amounts reported in the financial statements, including the notes thereto. As a result, management is required to routinely make judgments and estimates about the effects of matters that are inherently uncertain. Actual results may differ from these estimates under different conditions or assumptions. Management determined there were no critical accounting estimates.
| 20 |
| Item 3. | Quantitative and Qualitative Disclosures About Market Risk |
We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.
| Item 4. | Controls and Procedures |
Evaluation of Disclosure Controls and Procedures and Changes in Internal Control over Financial Reporting
We maintain a set of disclosure controls and procedures designed to ensure that material information required to be disclosed in our filings under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that material information is accumulated and communicated to our management, including our chief executive officer, who serves as our principal executive officer, and our chief financial officer, who serves as our principal financial officer, as appropriate, to allow timely decisions regarding required disclosures.
Under the supervision, and with the participation of our management, including our chief executive officer and our chief financial officer, we conducted an evaluation of the effectiveness, as of September 30, 2026, of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
Based upon such evaluation, our chief executive officer and our chief financial officer have concluded that, as of September 30, 2026, our disclosure controls and procedures were, and continue to be, ineffective because of the material weaknesses in our internal control over financial reporting primarily due to lack of segregation of duties (resulting from the limited number of personnel available). Previously, we identified having limited access to timely and complete information regarding the status of costs incurred in the activation of investigational sites and costs from treating patients in our Berubicin study, which is a result of the use of a third-party Contract Research Organization (“CRO”) to manage the study, and the lack of formal documentation of our control environment. The Berubicin study is complete and all sites have been closed out, which eliminated this as a contributing factor to our material weakness. Management has commenced and is undertaking actions to address the lack of formal documentation of our control environment, although this will not address the lack of segregation of duties.
A material weakness is a control deficiency (within the meaning of the Public Company Accounting Oversight Board (“PCAOB”) Auditing Standard 1305) or combination of control deficiencies that result in a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected.
It should be noted that any system of controls, however well designed and operated, can provide only reasonable and not absolute assurance that the objectives of the system are met. In addition, the design of any control system is based in part upon certain assumptions about the likelihood of certain events. Because of these and other inherent limitations of control systems, there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote.
In light of the material weakness described above, we performed additional analysis and other post-closing procedures to ensure our financial statements were prepared in accordance with generally accepted accounting principles. Accordingly, we believe that the financial statements included in this report fairly present, in all material respects, our financial condition, results of operations and cash flows for the periods presented.
Other than as described above, there has been no change in our internal control over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
| 21 |
PART II - OTHER INFORMATION
| Item 1. | Legal Proceedings |
From time to time in the ordinary course of our business, we may be involved in legal proceedings, the outcomes of which may not be determinable. The results of litigation are inherently unpredictable. Any claims against us, whether meritorious or not, could be time consuming, result in costly litigation, require significant amounts of management time and result in diversion of significant resources. We are not able to estimate an aggregate amount or range of reasonably possible losses for those legal matters for which losses are not probable and estimable. We have insurance policies covering potential losses where such coverage is cost effective.
We are not at this time involved in any legal proceedings.
| Item 1A. | Risk Factors |
In addition to the other information set forth in this report, you should carefully consider the factors set forth in the section entitled “Risk Factors” in our 2025 Annual Report on Form 10-K, filed with the SEC, which are incorporated herein by reference. The risks described in such reports are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.
| Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds |
Except as previously disclosed on Form 8-K, we have not issued any unregistered securities during the quarter ended September 30, 2026.
| Item 3. | Defaults Upon Senior Securities |
None.
| Item 4. | Mine Safety Disclosures |
Not applicable.
| Item 5. | Other Information |
During the period covered by this Quarterly
Report, none of the Company’s directors or officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as
amended) has
| 22 |
| Item 6. | Exhibits |
INDEX TO EXHIBITS
|
Exhibit Number |
Description | |
| 10.1 | Form of Indemnification Agreement (filed as Exhibit 10.4 to the Company’s Form 10-Q filed August 12, 2026) | |
| 31.1* | Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934. | |
| 31.2* | Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934. | |
| 32.1*(1) | Certification of the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |
| 32.2*(1) | Certification of the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |
| 101.INS* | Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document) | |
| 101.SCH* | Inline XBRL Taxonomy Extension Schema Document | |
| 101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |
| 101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document | |
| 101.LAB* | Inline XBRL Taxonomy Extension Label Linkbase Document | |
| 101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |
| 104* | Cover Page Interactive Data File (formatted in iXBRL, and included in exhibit 101). |
______________
| * | Filed herewith. |
| (1) | The certifications on Exhibit 32 hereto are deemed not “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that Section. Such certifications will not be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act. |
| 23 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
CNS PHARMACEUTICALS, INC.
| SIGNATURE | TITLE | DATE | ||
| /s/ Rami Levin | Chief Executive Officer, President | November 16, 2026 | ||
| Rami Levin | (Principal Executive Officer) | |||
| /s/ Steve O’Loughlin | Chief Financial Officer | November 16, 2026 | ||
| Steve O’Loughlin | (Principal Financial and Accounting Officer) |
| 24 |